Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib
(Source: Annals of Hematology)
Source: Annals of Hematology - December 15, 2023 Category: Hematology Source Type: research
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
AbstractDespite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asym...
Source: Annals of Hematology - December 14, 2023 Category: Hematology Source Type: research
Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series report
AbstractImmune thrombocytopenia (ITP) is a common bleeding disorder in children. First-line medicines (glucocorticoids and immunoglobulin) may not be effective for some children, endangering their lives, posing challenges for healthcare facilities, and leading to an unfavorable prognosis. As a sialidase inhibitor, oseltamivir phosphate can reduce the destruction of platelets in liver macrophages by inhibiting the sialylation of platelets, and finally achieve the purpose of increasing platelet count. In this paper, three cases of children with ITP who failed first-line therapy and were cured by oral administration of oselta...
Source: Annals of Hematology - December 14, 2023 Category: Hematology Source Type: research
Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma
AbstractNatural killer/T ‐cell lymphoma (NKTCL) is an aggressive and malignant condition with a high mortality rate. Prognostic factors may assist to evaluate the outcome of the disease and may also be useful in selecting appropriate therapeutic strategies for patients. The study aims to describe NKTCL in terms of its cli nical features, laboratory examinations, and immunophenotypes and to analyze relevance affecting patient survival outcomes. The patients diagnosed as NKTCL in Jinling Hospital from Jan. 2012 to Dec. 2022 were reviewed retrospectively in this study basing on histopathology. The analysis was performed to ...
Source: Annals of Hematology - December 14, 2023 Category: Hematology Source Type: research
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
AbstractDespite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asym...
Source: Annals of Hematology - December 14, 2023 Category: Hematology Source Type: research
Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series report
AbstractImmune thrombocytopenia (ITP) is a common bleeding disorder in children. First-line medicines (glucocorticoids and immunoglobulin) may not be effective for some children, endangering their lives, posing challenges for healthcare facilities, and leading to an unfavorable prognosis. As a sialidase inhibitor, oseltamivir phosphate can reduce the destruction of platelets in liver macrophages by inhibiting the sialylation of platelets, and finally achieve the purpose of increasing platelet count. In this paper, three cases of children with ITP who failed first-line therapy and were cured by oral administration of oselta...
Source: Annals of Hematology - December 14, 2023 Category: Hematology Source Type: research
Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma
AbstractNatural killer/T ‐cell lymphoma (NKTCL) is an aggressive and malignant condition with a high mortality rate. Prognostic factors may assist to evaluate the outcome of the disease and may also be useful in selecting appropriate therapeutic strategies for patients. The study aims to describe NKTCL in terms of its cli nical features, laboratory examinations, and immunophenotypes and to analyze relevance affecting patient survival outcomes. The patients diagnosed as NKTCL in Jinling Hospital from Jan. 2012 to Dec. 2022 were reviewed retrospectively in this study basing on histopathology. The analysis was performed to ...
Source: Annals of Hematology - December 14, 2023 Category: Hematology Source Type: research
Lymphocyte subsets and soluble forms of MIC-A and MIC-B are prognostic factors in non-Hodgkin lymphoma patients
In conclusion, high levels of sMIC and decreased numbers in circulating lymphocyte subsets are related to poor outcomes in NHL. (Source: Annals of Hematology)
Source: Annals of Hematology - December 13, 2023 Category: Hematology Source Type: research
Optimal dosage of rituximab for children with Burkitt lymphoma
This study aimed to explore optimal therapeutic strategies—the nu mber of doses of rituximab based on different risk groups—and also aim to investigate the clinical characteristics of Chinese pediatric BL. This study consecutively enrolled children with BL in Beijing Children’s Hospital who received French-American-British mature B-cell lymphoma 96 (FAB/LMB96) . The patients were divided into three groups: R0 group (chemotherapy alone), R6 group (chemotherapy combined with six rituximab doses), and R4 group (chemotherapy combined with four rituximab doses). The clinical characteristics and outcomes were evaluated. Un...
Source: Annals of Hematology - December 13, 2023 Category: Hematology Source Type: research
Lymphocyte subsets and soluble forms of MIC-A and MIC-B are prognostic factors in non-Hodgkin lymphoma patients
In conclusion, high levels of sMIC and decreased numbers in circulating lymphocyte subsets are related to poor outcomes in NHL. (Source: Annals of Hematology)
Source: Annals of Hematology - December 13, 2023 Category: Hematology Source Type: research
Optimal dosage of rituximab for children with Burkitt lymphoma
This study aimed to explore optimal therapeutic strategies—the nu mber of doses of rituximab based on different risk groups—and also aim to investigate the clinical characteristics of Chinese pediatric BL. This study consecutively enrolled children with BL in Beijing Children’s Hospital who received French-American-British mature B-cell lymphoma 96 (FAB/LMB96) . The patients were divided into three groups: R0 group (chemotherapy alone), R6 group (chemotherapy combined with six rituximab doses), and R4 group (chemotherapy combined with four rituximab doses). The clinical characteristics and outcomes were evaluated. Un...
Source: Annals of Hematology - December 13, 2023 Category: Hematology Source Type: research
Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study
This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015 –2019, to characterize adult patients newly diagnosed with MM, and to follow-up their overall survival (OS) and treatment patterns until the end of 2020. We sourced the data on inpatient and outpatient diagnoses, outpatient medication use, and date of death from comprehensive, nationwide registers . We identified 2037 incident patients with MM in 2015–2019. On average, the annual crude incidence was 8.8 and the age-standardized incidence (World Standard Population) was 3.3 per 100,000. The crude prevalence at the end ...
Source: Annals of Hematology - December 12, 2023 Category: Hematology Source Type: research
Clinical characteristics of hepatitis-associated aplastic anemia in children
AbstractTo understand the current situation of hepatitis-related aplastic anemia (HAAA) in children, we analyzed the patients with HAAA admitted to our hospital in the past 5 years to understand the disease characteristics and prognosis. The clinical data of patients with HAAA admitted to our hospital from February 2017 to May 2022 were retrospectively analyzed. A total of 81 patients with HAAA, 56 males and 25 females. The median onset age was 5.9 years. The median time from hepatitis to occurrence of hemocytopenia was 30 days, and the median follow-up time was 2.77 years. There were 23 cases (28.5%) of severe aplastic...
Source: Annals of Hematology - December 12, 2023 Category: Hematology Source Type: research
Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study
This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015 –2019, to characterize adult patients newly diagnosed with MM, and to follow-up their overall survival (OS) and treatment patterns until the end of 2020. We sourced the data on inpatient and outpatient diagnoses, outpatient medication use, and date of death from comprehensive, nationwide registers . We identified 2037 incident patients with MM in 2015–2019. On average, the annual crude incidence was 8.8 and the age-standardized incidence (World Standard Population) was 3.3 per 100,000. The crude prevalence at the end ...
Source: Annals of Hematology - December 12, 2023 Category: Hematology Source Type: research
